Sodium-glucose co-transport 2 (SGLT2) inhibitors are new therapeutic agents to cardiology.
Initially intended as treatment for diabetes mellitus, clinical trials to demonstrate
their cardiovascular safety have revealed significant cardiovascular benefits. The
mechanisms for these benefits remain hypothetical but appear pleiotropic. Their adverse
effect profile is diverse, with many being non-cardiovascular. This combination, along
with therapeutic inertia, may lead to limited uptake due to risk-benefit concerns.
To read this article in full you will need to make a payment
Purchase one-time access:
Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online accessOne-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
Subscribe:
Subscribe to Heart, Lung and CirculationAlready a print subscriber? Claim online access
Already an online subscriber? Sign in
Register: Create an account
Institutional Access: Sign in to ScienceDirect
Article info
Publication history
021
Identification
Copyright
© 2021 Published by Elsevier Inc.
